Chapter · Section VI
Chapter 30: Pharmaceutical products
- FreeUK
- 0%–6.5%EU
- 0%–150%Türkiye
- 0%–6.4%USA
- US$863.5bnWorld trade in 2024
6 headings make up chapter 30, part of section VI, products of the chemical or allied industries.
In the UK Global Tariff, chapter 30 covers 58 tariff lines and the duty is duty-free.
The EU Combined Nomenclature divides chapter 30 into 55 tariff lines; the duty is between 0% and 6.5% (average 0.3%). 52 of them are duty-free.
In the Turkish Customs Tariff Schedule, chapter 30 covers 91 tariff lines and the statutory rate is between 0% and 150%. 29 of them are duty-free.
World trade in chapter 30 goods reached US$863.5bn in 2024, up 3.6% on 2023.
Germany was the largest exporter with 13.5% of the total, ahead of the United States.
The United States imported the most (US$177bn).
Duty rates compared
The Turkish schedule prints the statutory rate set under Customs Law 474. The rate applied at import is laid down in the Import Regime Decision and can be lower, or different by country of origin.
Headings 6
- 3001Glands and other organs for organo-therapeutic uses, dried, whether or not powdered; extracts of glands or other organs or of their secretions for organo-therapeutic uses; heparin and its salts; other human or animal substances prepared for therapeutic or prophylactic uses, not elsewhere specified or included
- 3002Human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) and similar products; cell cultures, whether or not modified
- 3003Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale
- 3004Medicaments (excluding goods of heading 3002, 3005 or 3006) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale
- 3005Wadding, gauze, bandages and similar articles (for example, dressings, adhesive plasters, poultices), impregnated or coated with pharmaceutical substances or put up in forms or packings for retail sale for medical, surgical, dental or veterinary purposes
- 3006Pharmaceutical goods specified in note 4 to this chapter
World trade in 2024
Trade value (US$) no reported trade < US$5.8mUS$5.8m+US$470.2m+US$6.3bn+> US$40.1bn
Exports: 220
- Germany: US$116.8bn
- United States: US$93.8bn
- Switzerland: US$90.5bn
- Ireland: US$87.8bn
- Italy: US$53bn
- Belgium: US$50.1bn
- France: US$40.1bn
- Netherlands: US$34.6bn
- India: US$27.2bn
- United Kingdom: US$26.5bn
- Slovenia: US$25.8bn
- Spain: US$21.6bn
- Austria: US$19.4bn
- Denmark: US$19.1bn
- China: US$17.1bn
- Singapore: US$15.7bn
- Japan: US$15bn
- Sweden: US$14.6bn
- Hungary: US$12.2bn
- Canada: US$11.7bn
- South Korea: US$11.3bn
- Poland: US$6.3bn
- Czechia: US$4.2bn
- Portugal: US$3.8bn
- Finland: US$3.2bn
- Greece: US$3.2bn
- Australia: US$3.1bn
- Mexico: US$3.1bn
- Israel: US$2.7bn
- Türkiye: US$2.7bn
- Romania: US$2.1bn
- Brazil: US$1.5bn
- Bulgaria: US$1.4bn
- Croatia: US$1.4bn
- Lithuania: US$1.3bn
- Norway: US$1.1bn
- Argentina: US$1.1bn
- Hong Kong SAR China: US$991.3m
- Taiwan: US$979.2m
- Slovakia: US$917.5m
- Thailand: US$773.1m
- Indonesia: US$754.2m
- Malta: US$721.6m
- Latvia: US$703m
- Malaysia: US$604.6m
- Saudi Arabia: US$601.8m
- Cyprus: US$559.6m
- Russia: US$552.1m
- South Africa: US$543.8m
- Egypt: US$516.3m
- Pakistan: US$510.1m
- Jordan: US$500.5m
- Costa Rica: US$493.3m
- New Zealand: US$482.8m
- Dominican Republic: US$470.2m
- Serbia: US$458.6m
- Colombia: US$428.1m
- Guatemala: US$421.6m
- United Arab Emirates: US$354.9m
- Iceland: US$322.7m
Trade value (US$) no reported trade < US$268.6mUS$268.6m+US$1.6bn+US$8bn+> US$31.2bn
Imports: 225
- United States: US$177bn
- Germany: US$71.1bn
- Switzerland: US$66.7bn
- Belgium: US$44.8bn
- China: US$38.5bn
- Italy: US$31.9bn
- France: US$31.2bn
- Japan: US$29.5bn
- Netherlands: US$29.1bn
- United Kingdom: US$28.4bn
- Spain: US$22bn
- Canada: US$17.2bn
- Ireland: US$13.2bn
- Poland: US$12.4bn
- Austria: US$12bn
- Russia: US$11.8bn
- Brazil: US$11.8bn
- Slovenia: US$11bn
- Australia: US$10.8bn
- South Korea: US$9bn
- Hungary: US$8.3bn
- Mexico: US$8.2bn
- Saudi Arabia: US$8bn
- Czechia: US$7.3bn
- Sweden: US$7.2bn
- Denmark: US$6.8bn
- Romania: US$6.6bn
- Türkiye: US$5.7bn
- Taiwan: US$5.3bn
- Singapore: US$4.7bn
- Greece: US$4.2bn
- United Arab Emirates: US$4.2bn
- Portugal: US$4.1bn
- Egypt: US$3.7bn
- Hong Kong SAR China: US$3.7bn
- Colombia: US$3.7bn
- Israel: US$3.6bn
- Vietnam: US$3.3bn
- India: US$2.9bn
- Thailand: US$2.8bn
- Slovakia: US$2.8bn
- Norway: US$2.7bn
- Malaysia: US$2.5bn
- South Africa: US$2.5bn
- Argentina: US$2.5bn
- Finland: US$2.4bn
- Ukraine: US$2.4bn
- Bulgaria: US$2.3bn
- Chile: US$2.3bn
- Kazakhstan: US$2.2bn
- Philippines: US$2.1bn
- Croatia: US$2.1bn
- Kuwait: US$2.1bn
- Lithuania: US$1.9bn
- Serbia: US$1.8bn
- Uzbekistan: US$1.6bn
- Iraq: US$1.6bn
- Algeria: US$1.5bn
- New Zealand: US$1.4bn
- Indonesia: US$1.3bn
Top exporters
| Rank | Country | Value | Share |
|---|---|---|---|
| 1 | US$116.8bn | 13.5% | |
| 2 | US$93.8bn | 10.9% | |
| 3 | US$90.5bn | 10.5% | |
| 4 | US$87.8bn | 10.2% | |
| 5 | US$53bn | 6.1% | |
| 6 | US$50.1bn | 5.8% | |
| 7 | US$40.1bn | 4.6% | |
| 8 | US$34.6bn | 4% | |
| 9 | US$27.2bn | 3.1% | |
| 10 | US$26.5bn | 3.1% |
Top importers
| Rank | Country | Value | Share |
|---|---|---|---|
| 1 | US$177bn | 20.5% | |
| 2 | US$71.1bn | 8.2% | |
| 3 | US$66.7bn | 7.7% | |
| 4 | US$44.8bn | 5.2% | |
| 5 | US$38.5bn | 4.5% | |
| 6 | US$31.9bn | 3.7% | |
| 7 | US$31.2bn | 3.6% | |
| 8 | US$29.5bn | 3.4% | |
| 9 | US$29.1bn | 3.4% | |
| 10 | US$28.4bn | 3.3% |
Chapter notes
Notes
1. This chapter does not cover:
(a) foods or beverages (such as dietetic, diabetic or fortified foods, food supplements, tonic beverages and mineral waters), other than nutritional preparations for intravenous administration (Section IV);
(b) products, such as tablets, chewing gum or patches (transdermal systems), containing nicotine and intended to assist tobacco use cessation (heading 2404);
(c) plasters specially calcined or finely ground for use in dentistry (heading 2520);
(d) aqueous distillates or aqueous solutions of essential oils, suitable for medicinal uses (heading 3301);
(e) preparations of headings 3303 to 3307, even if they have therapeutic or prophylactic properties;
(f) soap or other products of heading 3401 containing added medicaments;
(g) preparations with a basis of plaster for use in dentistry (heading 3407);
(h) blood albumin not prepared for therapeutic or prophylactic uses (heading 3502); or
(ij) diagnostic reagents of heading 3822.
2. For the purposes of heading 3002, the expression ‘immunological products’ applies to peptides and proteins (other than goods of heading 2937) which are directly involved in the regulation of immunological processes, such as monoclonal antibodies (MAB), antibody fragments, antibody conjugates and antibody fragment conjugates, interleukins, interferons (IFN), chemokines and certain tumour-necrosis factors (TNF), growth factors (GF), hematopoietins and colony-stimulating factors (CSF).
3. For the purposes of headings 3003 and 3004 and of note 4(d) to this chapter, the following are to be treated:
(a) as unmixed products:
(1) unmixed products dissolved in water;
(2) all goods of Chapter 28 or 29; and
(3) simple vegetable extracts of heading 1302, merely standardised or dissolved in any solvent;
(b) as products which have been mixed:
(1) colloidal solutions and suspensions (other than colloidal sulphur);
(2) vegetable extracts obtained by the treatment of mixtures of vegetable materials; and
(3) salts and concentrates obtained by evaporating natural mineral waters.
4. Heading 3006 applies only to the following, which are to be classified in that heading and in no other heading of the nomenclature:
(a) sterile surgical catgut, similar sterile suture materials (including sterile absorbable surgical or dental yarns) and sterile tissue adhesives for surgical wound closure;
(b) sterile laminaria and sterile laminaria tents;
(c) sterile absorbable surgical or dental haemostatics; sterile surgical or dental adhesion barriers, whether or not absorbable;
(d) opacifying preparations for X-ray examinations and diagnostic reagents designed to be administered to the patient, being unmixed products put up in measured doses or products consisting of two or more ingredients which have been mixed together for such uses;
(e) placebos and blinded (or double-blinded) clinical trial kits for use in recognised clinical trials, put up in measured doses, even if they might contain active medicaments;
(f) dental cements and other dental fillings; bone reconstruction cements;
(g) first-aid boxes and kits;
(h) chemical contraceptive preparations based on hormones, on other products of heading 2937 or on spermicides;
(ij) gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments;
(k) waste pharmaceuticals, that is, pharmaceutical products which are unfit for their original intended purpose due to, for example, expiry of shelf life; and
(l) appliances identifiable for ostomy use, that is, colostomy, ileostomy and urostomy pouches cut to shape and their adhesive wafers or faceplates.
Subheading notes
1. For the purposes of subheadings 300213 and 300214, the following are to be treated:
(a) as unmixed products, pure products, whether or not containing impurities;
(b) as products which have been mixed:
(1) the products mentioned in (a) above dissolved in water or in other solvents;
(2) the products mentioned in (a) and (b) (1) above with an added stabiliser necessary for their preservation or transport; and
(3) The products mentioned in (a), (b) (1) and (b) (2) above with any other additive.
2. Subheadings 300360 and 300460 cover medicaments containing artemisinin (INN) for oral ingestion combined with other pharmaceutical active ingredients, or containing any of the following active principles, whether or not combined with other pharmaceutical active ingredients : amodiaquine (INN); artelinic acid or its salts; artenimol (INN); artemotil (INN); artemether (INN); artesunate (INN); chloroquine (INN); dihydroartemisinin (INN); lumefantrine (INN); mefloquine (INN); piperaquine (INN); pyrimethamine (INN) or sulfadoxine (INN).
Additional note
1. Heading 3004 includes herbal medicinal preparations and preparations based on the following active substances: vitamins, minerals, essential amino-acids or fatty acids, in packings for retail sale. These preparations are classified in heading 3004 if they bear on the label, packaging or on the accompanying user directions the following statements of:
(a) the specific diseases, ailments or their symptoms for which the product is to be used;
(b) the concentration of active substance or substances contained therein;
(c) dosage; and
(d) mode of application.
This heading includes homeopathic medicinal preparations when they meet the conditions of (a), (c) and (d) mentioned above.
In the case of preparations based on vitamins, minerals, essential amino-acids or fatty acids, the level of one of these substances per recommended daily dose indicated on the label must be significantly higher than the recommended daily allowance to maintain general health or well-being.
Products classified here
Questions and answers
What is the HS code for pharmaceutical products?
Pharmaceutical products make up HS chapter 30, in section VI of the Harmonized System.
What is the import duty on pharmaceutical products in the UK?
Under the UK Global Tariff, imports under 30 from countries without a preferential agreement are free of duty. Preferential rates, anti-dumping duties and VAT are not included.
What is the import duty on pharmaceutical products in the EU?
Under the EU Combined Nomenclature, imports under 30 from countries without a preferential agreement are charged at 0% to 6.5%, depending on the line. Preferential rates, anti-dumping duties and VAT are not included.
Which country exports the most pharmaceutical products?
Germany, with US$116.8bn in 2024 (13.5% of world exports).